Search company, investor...

Compare Cardax Pharmaceuticals vs Nuon Therapeutics

Customers evaluate the quality of Cardax Pharmaceuticals's products using the following success metrics.

Overview

Cardax Pharmaceuticals is 18 yrs old and is based in United States.

Cardax Pharmaceuticals is developing a platform of proprietary small molecule compounds for unmet medical needs where oxidative stress and inflammation play causative roles. The company's platform includes CDX-085 with application in metabolic syndrome, arthritis, and cardiovascular disease, as well as other prodrugs for macular degeneration and prostate disease.

Nuon Therapeutics is 22 yrs old and is based in United States.

Nuon Therapeutics discovers novel uses for marketed drugs. The advantage of this approach is that the development program for the marketed indication will have investigated the compounds toxicity and established its tolerability. This makes it possible to proceed directly to clinical trials once the efficacy of the compound has been established in animal models. The costs and risks involved in the drug development process are greatly reduced. Tranilast is under development for the treatment of patients with multiple sclerosis. The only drugs available for the treatment of patients with relapsing-remitting and secondary- progressive multiple sclerosis are interferon-beta, glatiramer acetate and mitoxantrone which reduce the number of relapses and the rate of disease progression. Tysabri is a monoclonal antibody for the treatment of patients with relapsing forms of multiple sclerosis. There is an urgent need for new therapies which can be orally administered and are more cost effective. Tranilast inhibits antigen-specific T cell proliferation, skews a TH1-type T cell response to TH2 and suppresses the activation of antigen presenting cells by interfering with signal transducer and activator of transcription (STAT) pathways. The oral administration of Tranilast reverses paralysis in mice with established experimental autoimmune encephalomyelitis.

Country

United States

Demo Video

Demo not available because Cardax Pharmaceuticals has not claimed their profile.

Work for Cardax Pharmaceuticals? Show off your product.

Demo not available because Nuon Therapeutics has not claimed their profile.

Work for Nuon Therapeutics? Show off your product.

Leadership

David G Watumull (Chief Executive Officer, President)

See all 2 people

Rodney Pearlman (Chief Executive Officer)

See all 5 people

Funding

Nuon Therapeutics last raised $10M on 8/19/2010.

Stage

Unattributed VC

Investors

Koffee Korner, Hawaii Angels

See all 4 investors

GBS Venture Partners, Frazier Healthcare Partners

See all 3 investors

Product

Benefits

Products

Customers

Known Partners

Why They Buy

Information not available because Cardax Pharmaceuticals has not claimed their profile.

Work for Cardax Pharmaceuticals? Claim your profile by submitting an Analyst Briefing. By submitting you can

Show your primary competitive advantage
Highlight your competitive differentiation
Show why customers evalute your products
Explain why customers choose your products and services

Work for Cardax Pharmaceuticals?

Claim your profile now.

Information not available because Nuon Therapeutics has not claimed their profile.

Work for Nuon Therapeutics? Claim your profile by submitting an Analyst Briefing. By submitting you can

Show your primary competitive advantage
Highlight your competitive differentiation
Show why customers evalute your products
Explain why customers choose your products and services

Work for Nuon Therapeutics?

Claim your profile now.